[go: up one dir, main page]

WO2007035621A1 - Seringue oculaire - Google Patents

Seringue oculaire Download PDF

Info

Publication number
WO2007035621A1
WO2007035621A1 PCT/US2006/036260 US2006036260W WO2007035621A1 WO 2007035621 A1 WO2007035621 A1 WO 2007035621A1 US 2006036260 W US2006036260 W US 2006036260W WO 2007035621 A1 WO2007035621 A1 WO 2007035621A1
Authority
WO
WIPO (PCT)
Prior art keywords
barrel
needle
injection solution
syringe
less
Prior art date
Application number
PCT/US2006/036260
Other languages
English (en)
Inventor
Stephen Scypinski
Perry Calias
Richard R. Everett
David T. Shima
Wisam Breegi
Dana L. Litman
Original Assignee
(Osi) Eyetech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (Osi) Eyetech, Inc. filed Critical (Osi) Eyetech, Inc.
Priority to JP2008531405A priority Critical patent/JP2009508593A/ja
Priority to EP06803774A priority patent/EP1924309A1/fr
Priority to CA002622573A priority patent/CA2622573A1/fr
Publication of WO2007035621A1 publication Critical patent/WO2007035621A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M2005/3201—Coaxially assembled needle cannulas placed on top of another, e.g. needles having different diameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3202—Devices for protection of the needle before use, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/34—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub
    • A61M5/347—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub rotatable, e.g. bayonet or screw

Definitions

  • the present invention relates to methods of administering ophthalmic medicines and devices related thereto.
  • the invention relates to intravitreous injection using an ophthalmic syringe and needle.
  • Intravitreous (FVT) injection has been used in the treatment of human ocular disease for nearly a century beginning in 1911 as means to introduce air for retinal tamponade and repair of detachment (J. Ohm, Albrecht von Graefes Arch Ophthalmol 1911; 79:442-450). Over the past two decades, the use of intravitreous injection has gained increasing acceptance in the therapeutic management of many intraocular diseases, particularly disorders affecting the posterior segment of the eye (Jager et ah, Retina 24:676-698, 2004). IVT injection is increasingly being incorporated into management of ocular diseases and the number of approved products for IVT injection is anticipated to grow on the basis of promising results from ongoing clinical studies.
  • IVT injection of medicines and diagnostics include the achievement of maximum vitreous concentrations while minimizing toxicity attributed to systemic administration. While these advantages are becoming widely appreciated, the ophthalmology community turns its focus to various complications potentially associated with IVT injection. Risks of rVT injection, some vision threatening, include endophthalmitis, retinal detachment, ulceris/uveitis, inflammation, intraocular hemorrhage, ocular hypertension, hypotony, pneumatic retinopexy, and cataract (R.D. Jager et al., Retina 24:676-698, 2004 and CN. Ta, Retina, 24:699-705, 2004).
  • Endophthalmitis is a condition in which the tissues inside the eyeball become inflamed and is generally caused by bacterial infection.
  • the most common sources of bacteria causing postoperative endophthalmitis are believed to be the patient's conjunctiva or eyelids. Unless treated effectively, endophthalmitis can rapidly lead to severe vision loss or blindness.
  • the relative risks of developing postoperative endophthalmitis depend on a number of factors, including the presence of eyelid or conjunctival diseases, the patient's general health, the use of immunosuppressant medications, the type of intraocular surgery, and intraoperative complications. Of these factors, intraoperative complications, particularly breaks in the posterior capsule with vitreous loss, carry the greatest risk for the development of endophthalmitis.
  • IOP intra-ocular pressure
  • Particulate contaminants present in a drug, in a syringe, or in or on materials used at the time of injection also may have the potential to induce detrimental effects when injected into the vitreous. This has been demonstrated in the case of glove lubricants, which are highly inflammatory when injected into the posterior ocular chamber (H. S. Park, Korean J. Ophthalmol. 1991; 11:51-59).
  • IVT injections are continuing to evolve (L.P. Aiello et al, Retina, 24:S3-S19, 2004).
  • povidone iodine and an antibiotic are administered prior to IVT injection.
  • IVT injections are generally performed with a sterile surgical drape and lid speculum in place and a 27 or 30 gauge needle is typically used with an injection site 3.5-4.0 mm posterior to the limbus.
  • intravitreous injection of the vascular endothelial growth factor (VEGF) inhibitor, Macugen® has become available for the treatment of age-related macular degeneration.
  • intravitreous injections of triamcinolone acetonide are now commonly used for the treatment of macular edema.
  • VEGF vascular endothelial growth factor
  • Drug delivery into the eye is challenging because the anatomy, physiology and biochemistry of the eye includes several defensive barriers that render ocular tissues impervious to foreign substances.
  • Techniques used for administering active agents into the eye include systemic routes, intraocular injections, injections around the eye, intraocular implants, and topical applications. Patient acceptance and safety are key issues that play a key role as to which treatments are used.
  • Ocular bioavailability of drugs applied topically in formulations such as eye drops is very poor.
  • the absorption of drugs in the eye is severely limited by some protective mechanisms that ensure the proper functioning of the eye, and by other concomitant factors, for example: drainage of the instilled solutions; lacrhymation, tear evaporation; nonproductive absorption/adsorption such as conjunctival absorption, poor corneal permeability, binding by the lachrymal proteins, and metabolism.
  • in situ activated gel-forming systems are liquid vehicles that undergo a viscosity increase upon instillation in the eye, thus favoring pre-corneal retention. Such a change in viscosity can be triggered by a change in temperature, pH or electrolyte composition.
  • Mucoadhesive formulations are vehicles containing polymers that adhere via non-covalent bonds to conjunctival mucin, thus ensuring contact of the medication with the pre-corneal tissues until mucin turnover causes elimination of the polymer.
  • Ocular penetration enhancers are mainly surface active agents that are applied to the cornea to enhance the permeability of superficial cells by destroying the cell membranes and causing cell lysis in a dose-dependent manner.
  • Ophthalmic inserts are solid devices intended to be placed in the conjunctival sac and to deliver the drug at a comparatively slow rate.
  • Ocusert® by Alza Corporation, which is a diffusion unit consisting of a drug reservoir enclosed by two release- controlling membranes made of a copolymer.
  • M.F. Saettone provides a review of continued endeavors devoted to ocular delivery. ("Progress and Problems in Ophthalmic Drug Delivery", Business Briefing: Pharmatech, Future Drug Delivery, 2002, 167-171).
  • Such invasive intraocular administrations may not be favorable because they cause patient discomfort and sometimes fear, while risking permanent tissue damage.
  • a device which allows the simultaneous or sequential delivery of a therapeutic while requiring a single needle penetration would significantly reduce any needle associated complications.
  • the present invention provides a device for use in ophthalmology.
  • the present invention provides a device for use in intravitreous administration of ocular agents.
  • the present invention also provides methods of delivering one or more drags to a human eye.
  • the invention relates to ophthalmic drug delivery devices and features a device for delivery of a therapeutic agent to the eye of a mammal.
  • the invention features a drag delivery device for delivering a therapeutic compound to the eye and drag delivery methods related thereto.
  • the invention also features a syringe for intravitreal delivery and methods of using the syringe to treat an ophthalmic disease, disorder, or condition.
  • Figure 1 is a schematic representation of a needle assembly comprising a luer hub, a cannula and a needle tip having a standard bevel.
  • Figure 2 is a schematic representation of a needle assembly comprising a luer hub, a cannula and a needle tip shield.
  • Figure 3 is a schematic representation of a syringe and needle assembly comprising a low dead space hub assembly.
  • Figure 4 shows drawings of a first embodiment of a double barrel syringe.
  • Figure 5 shows drawings of a first embodiment of a double barrel syringe.
  • Figure 6 is a schematic representation of a fluid exchange device.
  • Figure 7 is a schematic representation of a tandem syringe.
  • Figure 8 is a graph showing penetration force required by various needles.
  • One aspect provides a syringe useful in ophthalmic applications for delivery of a material into the eye.
  • a needle typically includes an elongated tube with an outside surface, a proximal end, a distal end and an open bore therethrough.
  • the needle assembly 20 may have a hub 23 attached to the proximal end of the needle 22 that is used to attach the needle to a syringe.
  • the hub is a Luer hub.
  • the needle may be attached to the syringe permanently (e.g., staked) or may be attached to the syringe by a Luer fitting.
  • the Luer fitting may be a standard Luer fitting, Luer slip fitting or a Luer lock fitting.
  • the Luer fitting has either a tip (male) or hub (female) component, and provides the ability to insure leak-proof and mechanically secure connections to any other device having a mating Luer fitting.
  • Luer connectors can comprise round and tapered male and matching female mating surfaces. Luer connectors can form a locking configuration by adding a threaded locking collar to the male luer connector, which mates with ears on the female luer connector, thereby providing a positive "locked" connection. Luer fittings have several advantages.
  • Luer fittings provide compatibility among various medical devices, offering the clinician the benefits of choosing a preferred needle.
  • Luer-lock connections insure against possibility of needle coming off of the syringe during the injection procedure.
  • Standards for Luer fittings are described in American National Standard ANSI/HIMA MD 70.1-1983 and the International Standard ISO-594-1 and ISO-7886-1.
  • a non-standard Luer fitting may be used.
  • non-standard Luer fittings include, but are not limited to, the Tru-LokTM fluid transfer adaptor by Becton Dickinson.
  • Other non-standard fittings include Tyco Health Care, Kendall Monoject® low dead space (LDS) needles featuring tri bevel, anti-coring, stainless steel needles.
  • LDS low dead space
  • Examples of low waste space fittings are found in US Patent Nos. 6,840,291, 5,902,277 5,902,271, 5,902,270 5,902,269 5,782,803, the contents of each are hereby incorporated by reference in its entirety.
  • the needle may also be attached to the syringe via a ceramic coated tip (CCT) interface, i.e. 'press fit'.
  • CCT ceramic coated tip
  • the needle is beveled and coated with a suitable silicone.
  • the needle is a PrecisionGlide® needle available from Becton-Dickenson. Suitable PrecisionGlide® needles include but are not limited to a Vi inch 30 gauge needle and a 1 A inch 27 gauge needle.
  • the needle is a PrecisionGlide® shown in Figure 3. Referring to the figure, the needle comprises a polypropylene Luer hub 33 and a stainless steel cannula 34, lubricated with silicone, having a three-bevel point, attached to the hub via an epoxy joint.
  • the needle tip may have a standard bevel. In one embodiment, the needle may have more than one bevel. In one embodiment, the needle has three bevels. In one embodiment, the needle has five bevels. Examples of a five-bevel needle are described in US Patent No. 6,629,963, and 6,009,933, US patent Application publication Nos. 2044/0111066, 2004/0030303 and PCT Application No. 2005/016420 In one embodiment, the needle is a coated needle. In one embodiment, the needle is a lubricated needle. The needle optionally includes a lubricious coating applied to and adherent to the outside surface of the tube, as described in US Patent No. 5,911,711.
  • the coating is a silicone coating.
  • Any suitable silicone coating may be used. Examples of suitable coatings include, but are not limited to, those available from SurModics, Eden Prairie, MN (see US Patent Nos. 6,706,408, 6,669,994, 6,254,634 and 6,121,027).
  • the coating is a medicated coating.
  • the needle is a 27 gauge needle or smaller. In one embodiment the needle is a 30 gauge needle.
  • the needle has a length of less than 1 inch. In another embodiment, the needle has a length of about 0.5 inches.
  • the needle assembly 20 may comprises a needle tip shield 21 enclosing needle 22. Needle 22 is attached to luer hub 23 via epoxy joint 24.
  • the tip shield 21 is rigid. Examples of suitable rigid shields include but are not limited to those disclosed in US Patent No. 4,986,818. As depicted in Figure 2, the tip shield is not in contact with the needle tip. Needle tip shields in contact with the needle potentially dull the needle and wipe away any lubrication on the needle.
  • the tip shield comprises one or more apertures or is permeable to sterilizing gases. The apertures may facilitate sterilization by allowing sterilizing gasses or steam to access the interior of the needle shield.
  • the tip shield is synthetic isoprene, ethylene oxide (EtO) or hydrogen peroxide (H 2 O 2 ) permeable.
  • the syringe barrels, stoppers and plunger rod components and assemblies can also be gamma irradiated.
  • the needle tip shield comprises a polypropylene.
  • the needle tip shield comprises a styrene block thermoplastic elastomer.
  • the needles of the present invention are used for penetration of the scleral tissue for administration of the syringe contents into the vitreous.
  • the needles require a low penetration force.
  • the needles require a low penetration force with low variability.
  • the needles require a penetration force of less than 500 grams (g).
  • the needles require a penetration force of less than 100 grams (g).
  • the needles require a penetration force of less than 50 grams (g).
  • the needles require a penetration force with a variability range of
  • the needles require a penetration force with a variability range of +/- 50 g. In another embodiment, the needles require a penetration force with a variability range of +/- 20 g
  • the penetration force is reduced by reducing the needles coefficient of friction. In one embodiment the penetration force is reduced by using a lubricious coating on the needle.
  • the syringe barrel is typically made of glass or a thermoplastic material.
  • the syringe is a 1 mL Type I glass barrel syringe sealed with a bromobutyl rubber stopper. Examples of pre-filled syringes are found in US Patent No. 4,252,118.
  • the syringe is a BD Hypak SCF® syringe.
  • the syringe is a single dose, pre-filled syringe.
  • the syringe barrel has a volume of 1 mL or less.
  • the syringe barrel has a microliter volume.
  • the syringe barrels of the present invention may further be provided with graduations to assist in precision filling of the barrel.
  • the syringe is a plastic syringe.
  • the syringe comprises a cyclic olefin copolymer (COC).
  • the cyclic olefin copolymer is TopPac® (Schott).
  • the final Luer formation is made using a platinum wire.
  • the syringe is substantially free of tungsten. Staked needle production requires a small hole and seat for gluing in the needle. The small hole requires a high temperature tungsten pin. Some of the tungsten pin material may shed into the glass during processing. Luer lock syringes are alternatively formed using a platinum pin material. The platinum may not leave a significant residue in the glass as compared to tungsten. Optimal particulate matter concentrations maybe achieved primarily through strict control of the environment and material cleanliness.
  • the ophthalmic injection solutions of the present invention are useful as microliter ( ⁇ L)-volume injections. Microliter ( ⁇ L)-volume injections may also be referred to as "ultra- low volume injections".
  • the ophthalmic injection solution to be delivered has a volume of about 1.0 mL (1000 ⁇ L) or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 200 ⁇ L or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 100 ⁇ L or less. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 90 ⁇ L. In another embodiment the ophthalmic injection solution to be delivered has a volume of about 50 ⁇ L.
  • the ophthalmic injection solutions of the present invention including solutions constituted from sterile solids intended for parenteral use, as used herein are substantially free from particles that can be observed on visual inspection. There are also strict controls on sub-visible particulate matter for ophthalmic injections.
  • the ophthalmic injection solutions of the present invention can be tested by a light obscuration procedure or may be tested by a microscopic procedure as described in USP Chapter ⁇ 788>.
  • United States Pharmacopoeia (USP) Chapters ⁇ 788> Particulate Matter in Injections and ⁇ 789> Particulate Matter in Ophthalmic Solutions describe physical tests for the purpose of enumerating extraneous particles within specific size ranges.
  • USP28-NF23 National Formulary, 23 rd edition
  • the United States Pharmacopeial Convention, Inc (2005) is hereby incorporated by reference in its entirety.
  • the ophthalmic solution contained within the syringe of the present invention has a 10 ⁇ m ⁇ size or larger sub-visible particulate count of less than or equal to about 60 particles per mL, a 25 ⁇ m-size or larger sub-visible particulate count of less than or equal to about 10 particles per mL, or a 50 ⁇ m-size or larger sub-visible particulate count of less than or equal to about 5 particles per mL.
  • the concentration of sub- visible particulate matter is less than or equal to about 150 ppb.
  • the ophthalmic solution contained within the syringe of the present invention is subject to the particulate matter limits set forth in USP ⁇ 789> wherein the average number of particles present in the units tested does not exceed the values listed in Table 1.
  • the ophthalmic solution contained within the syringe of the present invention has a lO ⁇ m-size or larger sub-visible particulate count of less than or equal to about 20 particles per mL, a 25 ⁇ m-size or larger sub-visible particulate count of less than or equal to about 5 particles per mL, or a 50 ⁇ m-size or larger sub-visible particulate count of less than or equal to about 2 particles per mL.
  • the concentration of sub-visible particulate matter contained within the syringe of the present invention is less than or equal to about 150 ppb.
  • the syringe assembly has a low waste space, which is defined as the volume located in the syringe tip 31 of syringe barrel 32, needle hub 33 and needle cannula 34.
  • the International Standard ISO-7886-1 identifies the maximum waste space for a 3ml syringe tip to be 0.07 mL.
  • the needle/syringe combination of the present invention has a low waste space.
  • low waste space fittings are found in US Patent Nos. 6,840,291, 5,902,277 5,902,271, 5,902,270 5,902,269 5,782,803, the contents of each is hereby incorporated by reference in its entirety.
  • An example of a needle/syringe combination having a low waste space includes Tru-lokTM fluid transfer adaptors by Becton Dickinson (US Patent No. 6,840,291) and Monoject® low dead space (LDS) needles Tyco Health Care, Kendall (catalog Nos. 1188005058 and 1188001112) featuring tri bevel, anti-coring, stainless steel needles.
  • the needle/syringe combination of the present invention has a waste space of less than 0.1 mL. In one embodiment, the waste space is less than 0.05 mL. In another embodiment, the waste space is approx. 50-60 ⁇ L. In one embodiment, the waste space for the 1 mL Hypak Luer tip syringe is from about 0.040 to about 0.050 mL. In another embodiment, the waste space is less than 0.001 mL.
  • the syringe assembly may comprise a syringe tip cap.
  • the syringe tip cap is used to seal the barrel of a prefilled syringe.
  • the syringe tip cap is a plastic rigid tip cap.
  • suitable syringe tip caps include, but are not limited to, those found in US Patent Nos. 6,190,364; 6,196,998; 6,520,935 and 5,833,653; US patent Application Publication No. 2004/0215148 and US design patent Nos. 457954S1 and 493526S1.
  • the rigid tip cap is an elastomeric formulation comprising an elastomer, reinforcement and a curing system.
  • the elastomer is a synthetic isoprene blend
  • the reinforcement is an inert material
  • the curing system is a resin
  • the syringe tip cap comprises a chloro/bromobutyl rubber stopper.
  • Another aspect of the invention provides a syringe comprising more than one barrel.
  • the multiple barrel syringe may permit simultaneous, selective or sequential delivery of one or more different materials.
  • the syringe comprises a first and second barrel positioned in side- by-side relationship including a first and second plunger for telescoping movement within their respective chambers (see US Patent Application Publication No. 2004/0064102, which is herby incorporated by reference in its entirety).
  • the plungers are optionally connected to a common handle allowing for the dispensing of the materials from the two chambers simultaneously at the same rate, as disclosed, for example, in US Patent No. 5,792,103.
  • the plungers are detachably connected to the plunger stopper.
  • Figures 4 and 5 show examples of dual barrel syringes for the simultaneous or sequential delivery of two or more therapeutic agents.
  • the syringe includes a first barrel, a second barrel, and one or more needles. Each barrel contains a therapeutic agent dissolved or suspended in a liquid formulation.
  • first and second embodiments of the double barrel syringe which differ in the respect that the first embodiment ( Figure 4) is configured for direct filling of the first and second materials inside their respective barrels while the second embodiment ( Figures 5) is configured for insertion of pre-filled first and second carpules into the first and second barrels, respectively.
  • the syringe comprises first and second barrels 41, 42 each having an internal chamber 43, 44 for holding a quantity of first and second, liquefied materials therein, respectively.
  • the first and second barrels 41, 42 are arranged in side-by-side relationship with each other.
  • First and second plungers 45, 46 are positioned for sliding within the first and second barrels 41, 42 for telescoping movement therein, respectively.
  • the syringe tip 47 is located adjacent the distal ends of the first and second barrels 41, 42 and is in common, fluid communication therewith via exit orifices 48 and 49.
  • Tip 47 may be in the form of a needle directly attached to the syringe body, or may be in the form of a cannula which is attached to the syringe body via a Luer lock.
  • the syringe comprises first and second carpules 51, 52 removably insertable within said first and second barrels 53, 54, respectively.
  • First and second syringe needles 55, 56 located in the first and second barrels 53, 54 adjacent the distal ends thereof.
  • the first and second syringe needles 55, 56 pierce the carpule plug provided at the respective carpule distal end.
  • the first and second needles 55, 56 extend into the tip 57.
  • a single needle with two or more hollow bores may perform both injections or multiple needles may be used.
  • two cannulas, one affixed to one of each barrel may lead to the one needle.
  • the hollow bores may be arranged in a concentric pattern. In such a concentric pattern, one bore is for introduction of a first fluid into the vitreous, and one bore is for introduction of second fluid into the vitreous.
  • a second needle may be attached to the exterior of a first needle. Needles may be manufactured from standard materials, e.g., stainless steel, by methods known in the art.
  • FIG. 6 illustrates an apparatus comprising a first and second housing 61, 62 capable of accepting a first and second prefilled syringe 63, 64.
  • tandem syringe typically comprises two or more compartments within one external barrel.
  • tandem syringes include but are not limited to those found in US Patent Nos. 4,313,440; 4,715,854; 5,102,388; 5,298,024; 6,132,400; and US Patent Application Publication No. 2004/0167480, each of which is herby incorporated by reference in its entirety.
  • the tandem syringe comprises an outer first compartment including a first sealing member and an inner second compartment in which the first sealing member functions as the plunger for the outer first compartment (see Figure 7).
  • the outer first compartment 71 is filled with a first injection solution.
  • the inner second compartment 72 is filled with a second injection solution.
  • the inner second compartment comprises a first sealing member 73 and functions as the piston for the first compartment.
  • compartment 71 contains the final solution to be injected. Compartment 71 is first loaded separately, then assembled with the main housing forming compartment 72. Compartment 72 in then loaded with the first solution to be injected.
  • the syringes of the present invention have several advantages. Advantages include the benefits of ease of use, flexibility, cost effectiveness, patient comfort and safety.
  • An advantage of using a non-fixed needle/syringe combination, such as one using a Luer fitting, as described herein is the allowance for a choice of application needle. For example, a practitioner may select either a 27 or 30 gauge disposable needle.
  • a non-fixed needle is typically sharper than a fixed needle because the non-fixed needle will not be susceptible to dulling as a result of contact with the sheath needed for a fixed needle pre-filled syringe. Sharper needles reduce patient discomfort and reduce the risk of infection.
  • intratreous The grammatically correct and preferred term “intravitreous” is used herein and in the art.
  • intravitreal is used colloquially as an alternative to the term “intravitreous” for injections into the eye's vitreous humor between the lens and the retina.
  • Porate matter includes mobile, randomly sourced, extraneous substances, other than gas bubbles, that cannot be quantitated by chemical analysis because of the small amount of material they represent or because of their heterogeneous composition.
  • proximal The portion of the device that is toward the practitioner is termed “proximal” and the portion of the device that is toward the patient is termed “distal.”
  • Penetration force is the measure of force applied to the needle prior to the needle cutting the tissue. Penetration force is typically measured throughout the art in grams (g).
  • Drop force is a measure of force applied to the needle required to continue the penetration into the tissue.
  • An “Injection” is a preparation intended for parenteral administration. Injections include, but are not limited to, liquid preparations that are drag substances or solutions/suspensions thereof.
  • substantially constant pressure pressure that is constant with minor, temporary variations due to filling, emptying, or a change in osmotic pressure of the surrounding liquid.
  • Parenteral articles are preparations intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal, so that the active substances they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion.
  • Parenteral articles are prepared by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants (USP Chapter 1).
  • Standard- Volume Injection applies to an injection that is packaged in containers labeled as containing 100 mL or less.
  • Microliter-volume Injection or "Ultra-Low- Volume Injection” applies to an Injection that is packaged in containers labeled as containing 1.0 mL (1000 ⁇ L) or less.
  • the term "dead space” or “Waste space” is the volume of injection solution within the syringe/needle assembly containing any residual injection solution present following an injection that does not get evacuated from the syringe during the injection.
  • therapeutic agent any compound or mixture of compounds that provide a therapeutic effect for one or more diseases, disorders, or conditions.
  • Such compounds include, without limitation, small organic or inorganic molecules, proteins (e.g., antibodies), peptides, lipids (e.g., steroids) and nucleic acids (e.g., aptamers).
  • Therapeutic agents are, for example, antibiotics, analgesics, anti-inflammatory compounds, or any other compound for the treatment of a disease, disorder, or condition.
  • treating is meant the medical management of a patient with the intent that a cure, amelioration, or prevention of a disease, pathological condition, or disorder will result.
  • active treatment that is, treatment directed specifically toward improvement of a disease, pathological condition, or disorder
  • causal treatment that is, treatment directed toward removal of the cause of the disease, pathological condition, or disorder.
  • palliative treatment that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder
  • preventive treatment that is, treatment directed to prevention of the disease, pathological condition, or disorder
  • supportive treatment that is, treatment employed to supplement another specific therapy directed toward the improvement of the disease, pathological condition, or disorder.
  • treating also includes symptomatic treatment, that is, treatment directed toward constitutional symptoms of the disease, pathological condition, or disorder.
  • Ophthalmic solutions are sterile solutions, essentially free from foreign particles, suitably compounded and packaged for instillation or injection into the eye. Preparation of an ophthalmic solution requires careful consideration of such factors as the inherent toxicity of the drug itself, isotonicity value, the need for buffering agents, the need for a preservative (and, if needed, its selection), sterilization, and proper packaging.
  • the present invention can be used to deliver a therapeutic agent to any desired site, including, but not limited to, intraorbital, intraocular, intraaural, intratympanic, intrathecal, intracavitary, peritumoral, intratumoral, intraspinal, epidural, intracranial, and intracardial.
  • a device of the invention may be used in the treatment of any eye disease.
  • a device of the invention may also be used to direct a therapeutic agent to a particular eye tissue, e.g., the retina or the choroid.
  • the therapeutic agent or combination of agents will be chosen based on the disease, disorder, or condition being treated.
  • other compounds may be included for secondary effects, for example, an antibiotic to prevent microbial growth.
  • the amount and frequency of the dosage will depend on the disease, disorder, or condition being treated and the therapeutic agent employed. One skilled in the art can make this determination.
  • Therapeutic agents that maybe employed in the device of the invention include, without limitation, small molecules, hormones, proteins, peptides, aptamers, antibodies, lipids, glycolipids, DNA, RNA, PNA, enzymes, sugars, saccharides, glycoproteins, polymers, metalloproteases, transition metals, or chelators.
  • nucleic acid vectors can also be delivered wherein the nucleic acid may be expressed to produce a protein that may have a variety of pharmacological, physiological or immunological activities. Macromolecules with a molecular weight of about 5 kDa to about 500 kDa may also be used in accordance with the invention.
  • exemplary disease states include macular degeneration, diabetic retinopathy, glaucoma, optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, pannus, pterygium, macular edema, vascular retinopathy, retinal vein occlusion, histoplasmosis, ischemic retinal disease, retinal degeneration, uveitis, inflammatory diseases of the retina, keratitis, cytomegalovirus retinitis, an infection, conjunctivitis, cystoid macular edema, cancer, and proliferative vitreoretinopathy.
  • Classes of therapeutic agents include anti-infectives including, without limitation, antibiotics, antivirals, and antifungals; analgesics; antiallergenic agents; mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; decongestants; anti-glaucoma agents including, without limitation, adrenergics, beta-adrenergic blocking agents, alpha-adrenergic blocking agonists, parasympathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and protaglandins; antioxidants; nutritional supplements; angiogenesis inhibitors; antimetabolites; fibrinolytics; wound modulating agents; neuroprotective drags; angiostatic steroids; mydriatics; cyclopegic mydriatics; miotics; vasoconstrictors; vasodilators; anticlotting agents; anticancer agents; immunomodulatory agents; VEGF antagonists; immunosuppresant agents; and combinations and prodrugs thereof.
  • Specific therapeutic agents include MACUGEN® (pegaptanib sodium injection) as described in U.S. Patent No. 6,051,698, herein incorporated in its entirety by reference.
  • Pegaptanib sodium is also referred to as EYEOOl or NXl 838.
  • Pegaptanib sodium is a covalent conjugate of an oligonucleotide of twenty-eight nucleotides in length that terminates in a pentylamino linker, to which two 20-kilodalton (kDa) monomethoxypolyethylene glycol (PEG) units are covalently attached via the two amino groups on a lysine residue.
  • the molecular formula for pegaptanib sodium is C 2 ⁇ H 342 F 13 N 1 O 7 Na 28 O 188 P 2S (C 2 H 4 O) n (where n is approximately 900) and the molecular weight is approximately 50 kDa.
  • RNA ((2'-deoxy-2 ( - fluoro)C-G m -G m -AA-(2 ! -deoxy-2'-fluoro)U-(2 l -deoxy-2 t -fluoro)C-A m -G m -(2'-deoxy-2 / - fluoro)U-G m -A m -A m -(2'-deoxy-2 !
  • MACUGEN® pegaptanib sodium injection
  • Macugen is supplied in a single-dose, pre- filled syringe and is formulated as a 3.47 mg/mL solution, measured as the free acid form of the oligonucleotide.
  • the active ingredient is 0.3 mg of the free acid form of the oligonucleotide without polyethylene glycol, in a nominal volume of 90 ⁇ L. This dose is equivalent to 1.6 mg of pegaptanib sodium (PEGylated oligonucleotide) or 0.32 mg when expressed as the sodium salt form of the oligonucleotide moiety.
  • the product is a sterile, clear, preservative-free solution containing sodium chloride, monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, hydrochloric acid, and/or sodium hydroxide to adjust the pH and water for injection.
  • Macugen is formulated to have an osmolality of 280-360 mOsm/Kg, and a pH of 6-7.
  • Dosage levels of pegaptanib sodium on the order of about 1 ⁇ g/kg to 100 mg/kg of body weight per administration are useful in the treatment of neo vascular disorders.
  • pegaptanib sodium is administered at a dosage of about 0.1 mg to about 1.0 mg locally into the eye, wherein the treatment is effective to treat occult, minimally classic, and predominantly classic forms of wet macular degeneration.
  • the dosage range is about 0.3 mg to about 3 mg per eye, in some embodiments the dosage range is about 0.1 mg to about 1.0 mg per eye.
  • pegaptanib sodium is administered in a therapeutically effective amount of about 0.003 - 3.0 mg, 0.1 - 1.0 mg, or about 0.3 mg.
  • pegaptanib sodium is present in an ophthalmic injection solution formulation at a concentration ranging from 0.003 to 3.0 mg/mL.
  • the carrier comprises sodium phosphate and sodium chloride.
  • the carrier comprises 10 mM sodium phosphate and 0.9% sodium chloride.
  • the dose is effective to achieve a vitreous concentration of the anti-VEGF aptamer of about 10-30 ng/mL.
  • the dose is effective to maintain a vitreous concentration of the anti-VEGF aptamer of about 10-30 ng/mL throughout a 6 week dosing interval.
  • the anti-VEGF agent is an anti-VEGF aptamer and is administered at a dosage of less than 0.3 mg to about 0.003 mg locally into the eye. In some embodiments, the anti-VEGF aptamer is administered at a dosage less than about 0.30 mg. Examples of such formulations are found in US Patent Application Serial No. 60/692,727; which is hereby incorporated by reference in its entirety.
  • Specific therapeutic agents also include the anti-PDGF aptamer ARC- 127 (Archemix
  • a PEGylated, anti-PDGF aptamer having the sequence CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO: 10 from U.S. Patent No. 6,582,918, incorporated herein by reference in its entirety) having 2'-fluoro-2'- deoxyuridine at positions 6, 20 and 30, 2'-fluoiO-2'-deoxycytidine at positions 8, 21, 28, and 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31 , 2'-O-Methyl-2'- deoxyadenosine at position 22, hexaethylene-glycol phosphoramidite at "N" in positions 10 and 23, and an inverted orientation T (i.e., 3'-3'-linked) at position 32.
  • CAGGCUACGN CGTAGAGCAU CANTGATCCU GT SEQ ID NO: 10 from U.S. Patent No. 6,582,918, incorporated herein by reference in its entirety
  • a combination therapy for the treatment of ocular neovascular disorders using a VEGF antagonist and a PDGF antagonist is described in PCT Application No. WO 2005/020972, which is incorporated herein by reference in its entirety.
  • An example of such a therapy comprises the administration of a combination of Macugen® and ARC127.
  • the present invention features a method for treating a patient suffering from an ocular disease, which method includes the following steps: (a) administering to the patient an effective amount of an anti- VEGF aptamer; and (b) providing the patient with phototherapy, such as photodynamic therapy or thermal laser photocoagulation as further described in PCT WO 03/039404, incorporated in its entirety by reference.
  • phototherapy such as photodynamic therapy or thermal laser photocoagulation as further described in PCT WO 03/039404, incorporated in its entirety by reference.
  • the photodynamic therapy includes the steps of: (i) delivering a photosensitizer to the eye tissue of a patient; and (ii) exposing the photosensitizer to light having a wavelength absorbed by the photosensitizer for a time and at an intensity sufficient to inhibit neovascularization in the patient's eye tissue.
  • photosensitizers may be used, including but not limited to, benzoporphyrin derivatives (BPD), monoaspartyl chlorine, zinc phthalocyanine, tin etiopurpurin, tetrahydroxy tetraphenylporphyrin, and porfimer sodium (PHOTOFRIN), and green porphyrins.
  • therapeutic agents include 4,9(1 l)-pregnadien-17 ⁇ ,21-diol-3,20-dione, 4,9(11)- pregnadien-17 ⁇ ,21-diol-3,20-dione-21-acetate, combretastatin, timolol, betaxolol, atenolol, brimonidine, acetazolamide, methazolamide, dichlorphenamide, diamox, nimodipine, eliprodil, colchicine, vincristine, cytochalasin B, tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, erythromycin, sulfonamides, sulfacetamide, sulfamethizole, sulfisoxazole, fluconazole, nitrofura
  • a therapeutic agent may be present in any suitable formulation for delivery to the eye. Methods well known in the art for making formulations are found, for example, in Remington: The Science and Practice of Pharmacy (20th ed., A.R. Gennaro ed., Lippincott: Philadelphia, 2000). Therapeutic agents may be administered to humans, domestic pets, livestock, or other animals with a pharmaceutically acceptable diluent, carrier, or excipient.
  • Therapeutic formulations may be liquid solutions, suspensions, or other formulations deliverable via a needle.
  • Formulations may, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
  • the therapeutic agent may be admixed with a pharmaceutically acceptable carrier adapted to provide sustained release of the therapeutic agent.
  • Sustained release carriers include emulsions, suspensions, polymeric matrices, microspheres, microcapsules, microparticles, liposomes, multivesicular liposomes, lipospheres, hydrogels, salts, and polymers with the therapeutic agent reversibly bound electrostatically, chemically or by entrapment.
  • Suitable sustained release formulations which may be used are known in the art and are disclosed in, for example, U.S. Patent Nos.
  • Formulations of the drag may also include a transscleral diffusion promoting agent, such as dimethylsulfoxide, ethanol, dimethylformamide, propylene glycol, N- methylpyrolidone, oleic acid, isopropyl myristate, polar aprotic solvents, polar protic solvents, steroids, sugars, polymers, small molecules, charged small molecules, lipids, peptides, proteins, and surfactants.
  • a transscleral diffusion promoting agent such as dimethylsulfoxide, ethanol, dimethylformamide, propylene glycol, N- methylpyrolidone, oleic acid, isopropyl myristate, polar aprotic solvents, polar protic solvents, steroids, sugars, polymers, small molecules, charged small molecules, lipids, peptides, proteins, and surfactants.
  • a therapeutic agent may be optionally administered as a pharmaceutically acceptable salt, such as a non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry.
  • acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or the like.
  • Metal complexes include cations, such as divalent cations including calcium and magnesium, zinc, iron, and the like.
  • a therapeutic agent may be optionally administered as a pharmaceutically acceptable prodrug, e.g., an ester or amide.
  • the chemical compounds for use in such therapies may be produced and isolated as described herein or by any standard technique known to those in the field of medicinal chemistry.
  • Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the identified compound to patients suffering from a disease, disorder, or condition of the eye. Administration may begin before, during, or after the patient is symptomatic.
  • Macugen® ((OSI) Eyetech, Inc., NY, NY) is formulated at 0.3mg/90 ⁇ L having a tungsten particulate count of less than 150 ppb.
  • the solution is presented in USP Type I glass barrel syringes fitted with a Luer lock hub and sealed with a bromobutyl rubber plunger stopper.
  • the syringe is fitted with a Luer lock 27-gauge, multi-beveled, silicone coated needle with a rigid plastic outer shield.
  • the needle requires a penetration force of less than 100 g.
  • Macugen® (Eyetech Pharmaceuticals, NY, NY) is formulated at 0.3mg/90 ⁇ L, 0.03mg/90 ⁇ L or 0.003mg/90 ⁇ L and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper.
  • the syringe is fitted with a Luer lock 27-gauge needle with a rigid plastic outer shield.
  • the stoppered syringe is packaged in a foil pouch.
  • a plastic plunger rod and flange adapter are also supplied for administration purposes. These components are provided in a separate foil pouch. Use of the flange is optional and is not required to administer the injection.
  • the drug product is preservative-free and intended for single use by intravitreous injection only. The product should not be used if cloudy or if particles are present.
  • the drug product pegaptanib sodium is a ready-to-use sterile solution provided in a single-use glass syringe.
  • Administration of the syringe contents involves attaching the threaded plastic plunger rod to the rubber stopper inside the barrel of the syringe. The rubber end cap is then removed to allow administration of the product.
  • An optional flange is provided for administrative purposes.
  • Phenylephrine 1% Mydriacyl and 2.5% Phenylephrine are applied topically to the study eye to achieve adequate pupillary dilation. Two to three drops of 50% saline diluted 10% povidone- iodine (betadine) solution are instilled into the eye. In the event of allergy to iodine, a drop of topical antibiotic is placed on the conjunctiva in place of iodine.
  • a subconjunctival injection of 0.5 ml 2% xylocaine without epinephrine is administered in the inferotemporal quadrant in all patients - 3.0 to 3.5 mm from the limbus in aphakic/pseudophakic patients, and 3.5 to 4.0 mm in phakic patients.
  • Investigators are instructed to select one of two pre-injection procedures (Options A and B, below).
  • Options A and B For patients with iodine allergy, investigators are required follow Option A, instilling one additional drop of antibiotic instead of povidone- iodine.
  • topical antibiotic drops Prior to treatment, topical antibiotic drops are administered 3 times separated by at least 5 minutes within one hour prior to treatment.
  • the investigator instills two or three drops of 5% povidone-iodine into the eye. Using sterile gloves and cotton-tip applicators soaked in 5% povidone iodine, the investigator scrubs the eyelids, the upper and lower eyelid margins, and the caruncle 3 times. In the event of allergy to iodine, one additional drop of antibiotic is instilled instead of povidone-iodine.
  • the investigator waits at least 5 minutes after the last dose of antibiotic to perform a 5% povidone-iodine flush, irrigating the fornices and the caruncle with at least 10 cc of 5% povidone-iodine using a forced stream from a syringe connected to an angio-catheter to effect mechanical debridement.
  • the investigator isolates the ocular field with a drape, pinning the eyelashes to the eyelids, and places one or two drops of 5% povidone-iodine on the ocular surface at the intended treatment site.
  • An eyelid speculum is used for all injections.
  • Group 1 HYPAK 1 mL long syringe 27Ga five-bevel Vz inch needle
  • Group 2 HYPAK 1 mL long syringe 29Ga five-bevel 1 A inch needle
  • Group 3 BD ImL TB syringe paired with a 30Ga 1 A inch precision glide needle
  • a porcine eye is fixed in test stand and pressurized to standard conditions for blade tests to simulate live conditions.
  • the syringe is placed in the test position on the Instron device.
  • the crosshead speed is set to 150 millimeters per minute.
  • the needle is penetrated about Vz the way into the sclera.
  • the penetration location is about 6 mm below the center of the eye pointing toward the center axis of the eye.
  • a new eye is used for each test (60 eyes total).
  • the penetration force resulting from various needles are shown in Table 2 and Figure Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention a pour objet un dispositif destiné à un usage ophtalmologique. Plus particulièrement, la présente invention concerne un dispositif pour l’administration de produits oculaires dans le corps vitré. L’invention a également pour objet des procédés d’administration d’un ou de plusieurs médicaments à l’œil humain et de traitement d’une maladie, d’un trouble ou d’un état ophtalmique.
PCT/US2006/036260 2005-09-16 2006-09-18 Seringue oculaire WO2007035621A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008531405A JP2009508593A (ja) 2005-09-16 2006-09-18 眼科用シリンジ
EP06803774A EP1924309A1 (fr) 2005-09-16 2006-09-18 Seringue oculaire
CA002622573A CA2622573A1 (fr) 2005-09-16 2006-09-18 Seringue oculaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71786505P 2005-09-16 2005-09-16
US60/717,865 2005-09-16

Publications (1)

Publication Number Publication Date
WO2007035621A1 true WO2007035621A1 (fr) 2007-03-29

Family

ID=37478598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/036260 WO2007035621A1 (fr) 2005-09-16 2006-09-18 Seringue oculaire

Country Status (4)

Country Link
EP (1) EP1924309A1 (fr)
JP (1) JP2009508593A (fr)
CA (1) CA2622573A1 (fr)
WO (1) WO2007035621A1 (fr)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132212A3 (fr) * 2008-04-25 2010-03-18 The Regents Of The University Of California Dispositif pour stocker et injecter une greffe cornéenne
JP2011507631A (ja) * 2007-12-20 2011-03-10 ユニバーシティ オブ サザン カリフォルニア 治療薬を送達するための装置および方法
WO2012013587A1 (fr) * 2010-07-26 2012-02-02 Sanofi-Aventis Deutschland Gmbh Ensemble aiguille multiple pour un dispositif d'injection
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
AU2012101677B4 (en) * 2012-07-03 2012-12-20 Novartis Ag Device
AU2013100071B4 (en) * 2012-07-03 2013-03-28 Novartis Ag Device
AU2013100360B4 (en) * 2012-07-03 2013-05-16 Novartis Ag Device
WO2013178771A1 (fr) * 2012-06-01 2013-12-05 Novartis Ag Seringue
WO2014005728A1 (fr) * 2012-07-03 2014-01-09 Novartis Ag Seringue
EP2775971A1 (fr) * 2011-10-07 2014-09-17 Sanofi-Aventis Deutschland GmbH Dispositif d'injection intraoculaire
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
WO2015061341A1 (fr) * 2013-10-21 2015-04-30 Accuro Technologies Inc. Seringue à double cylindre et son procédé d'utilisation pour la confirmation de placement et injection dans un espace articulaire
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US9107995B2 (en) 2008-05-08 2015-08-18 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9199035B2 (en) 2008-05-08 2015-12-01 Minipumps, Llc. Drug-delivery pumps with dynamic, adaptive control
WO2016018889A1 (fr) * 2014-07-28 2016-02-04 Medical Instrument Development Laboratories, Inc. Glissière de renfort pour outil chirurgical manuel
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9623174B2 (en) 2008-05-08 2017-04-18 Minipumps, Llc Implantable pumps and cannulas therefor
US9693894B2 (en) 2006-03-14 2017-07-04 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10130777B2 (en) 2014-07-08 2018-11-20 Terumo Kabushiki Kaisha Injection needle
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US10328212B2 (en) 2016-04-22 2019-06-25 Accuro Technologies Inc. Single slider double barrel syringe and method to use same for medical diagnostics, therapeutic use, and placement confirmation and joint space injection
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10905786B2 (en) 2017-03-27 2021-02-02 Regeneron Pharmaceuticals, Inc. Sterilisation method
US11273171B2 (en) 2013-07-12 2022-03-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US11406565B2 (en) 2015-03-10 2022-08-09 Regeneran Pharmaceuticals, Inc. Aseptic piercing system and method
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11433186B2 (en) 2017-12-13 2022-09-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11439758B2 (en) 2019-06-05 2022-09-13 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11547801B2 (en) 2017-05-05 2023-01-10 Regeneron Pharmaceuticals, Inc. Auto-injector
US20230080971A1 (en) * 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
EP2548594B1 (fr) * 2011-07-22 2023-07-12 Piramal Critical Care Inc. Formes de dosage pharmaceutiques de baclofène intrathécal et système de distribution associé
KR20230110383A (ko) 2022-01-14 2023-07-24 건양대학교산학협력단 주사기
US11769597B2 (en) 2015-12-03 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200479125Y1 (ko) * 2014-07-11 2015-12-21 류승호 이중 니들형 주사기

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792099A (en) * 1995-02-14 1998-08-11 Decamp; Dennis Syringe and cannula for insertion of viscoelastic material into an eye and method of using same
US20030120201A1 (en) * 2001-12-21 2003-06-26 Abergel R. Patrick Methods and devices for sclerotherapy
WO2003089035A1 (fr) * 2002-04-16 2003-10-30 Imprint Pharmaceuticals Limited Aiguille a ouverture laterale
US20050148947A1 (en) * 2003-12-30 2005-07-07 Advanced Medical Optics, Inc. Cannula locking device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629963B2 (en) * 1996-06-20 2003-10-07 Becton, Dickinson And Company Syringe and needle shield assembly and method of sterilizing such assembly
JP2002095743A (ja) * 2000-09-22 2002-04-02 Terumo Corp 液体注入器具
WO2004073551A2 (fr) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Dispositif d'administration transsclerale de medicament et procedes associes
JP2005110735A (ja) * 2003-10-03 2005-04-28 Keizo Tanii 薬液充填用タンデム型２層化シリンジ製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792099A (en) * 1995-02-14 1998-08-11 Decamp; Dennis Syringe and cannula for insertion of viscoelastic material into an eye and method of using same
US20030120201A1 (en) * 2001-12-21 2003-06-26 Abergel R. Patrick Methods and devices for sclerotherapy
WO2003089035A1 (fr) * 2002-04-16 2003-10-30 Imprint Pharmaceuticals Limited Aiguille a ouverture laterale
US20050148947A1 (en) * 2003-12-30 2005-07-07 Advanced Medical Optics, Inc. Cannula locking device

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693894B2 (en) 2006-03-14 2017-07-04 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US9271866B2 (en) 2007-12-20 2016-03-01 University Of Southern California Apparatus and methods for delivering therapeutic agents
US9308124B2 (en) 2007-12-20 2016-04-12 University Of Southern California Apparatus and methods for delivering therapeutic agents
JP2011507631A (ja) * 2007-12-20 2011-03-10 ユニバーシティ オブ サザン カリフォルニア 治療薬を送達するための装置および方法
US10117774B2 (en) 2007-12-20 2018-11-06 University Of Southern California Apparatus and methods for delivering therapeutic agents
US8636795B2 (en) 2008-04-25 2014-01-28 The Regents Of The University Of California Device to store and inject corneal graft
WO2009132212A3 (fr) * 2008-04-25 2010-03-18 The Regents Of The University Of California Dispositif pour stocker et injecter une greffe cornéenne
US9283322B2 (en) 2008-05-08 2016-03-15 Minipumps, Llc Drug-delivery pump with dynamic, adaptive control
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US9861525B2 (en) 2008-05-08 2018-01-09 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9199035B2 (en) 2008-05-08 2015-12-01 Minipumps, Llc. Drug-delivery pumps with dynamic, adaptive control
US9162024B2 (en) 2008-05-08 2015-10-20 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9623174B2 (en) 2008-05-08 2017-04-18 Minipumps, Llc Implantable pumps and cannulas therefor
US9107995B2 (en) 2008-05-08 2015-08-18 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8298578B2 (en) 2009-01-29 2012-10-30 Forsight Vision4, Inc. Posterior segment drug delivery
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012013587A1 (fr) * 2010-07-26 2012-02-02 Sanofi-Aventis Deutschland Gmbh Ensemble aiguille multiple pour un dispositif d'injection
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
EP3960134A1 (fr) * 2010-08-05 2022-03-02 ForSight Vision4, Inc. Dispositif thérapeutique implantable
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
EP2548594B1 (fr) * 2011-07-22 2023-07-12 Piramal Critical Care Inc. Formes de dosage pharmaceutiques de baclofène intrathécal et système de distribution associé
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
EP2775971A1 (fr) * 2011-10-07 2014-09-17 Sanofi-Aventis Deutschland GmbH Dispositif d'injection intraoculaire
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10603209B2 (en) 2012-02-03 2020-03-31 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP3777834A1 (fr) * 2012-06-01 2021-02-17 Novartis AG Seringue
EP3536310A1 (fr) * 2012-06-01 2019-09-11 Novartis AG Seringue
US11185635B2 (en) 2012-06-01 2021-11-30 Novartis Ag Syringe
CN104780906A (zh) * 2012-06-01 2015-07-15 诺华股份有限公司 注射器
US12048837B2 (en) 2012-06-01 2024-07-30 Novartis Ag Syringe
US11179521B2 (en) 2012-06-01 2021-11-23 Novartis Ag Syringe
US11147925B2 (en) 2012-06-01 2021-10-19 Novartis Ag Syringe
US11110226B2 (en) 2012-06-01 2021-09-07 Novartis Ag Syringe
US11103644B2 (en) 2012-06-01 2021-08-31 Novartis Ag Syringe
EP3679922B1 (fr) 2012-06-01 2021-07-28 Novartis AG Seringue
EP3777834B1 (fr) 2012-06-01 2022-02-16 Novartis AG Seringue
EP3679922A1 (fr) * 2012-06-01 2020-07-15 Novartis AG Seringue
WO2013178771A1 (fr) * 2012-06-01 2013-12-05 Novartis Ag Seringue
EA033161B1 (ru) * 2012-06-01 2019-09-30 Новартис Аг Шприц
EP3656373B1 (fr) 2012-07-03 2022-02-16 Novartis AG Seringue
AU2013100360B4 (en) * 2012-07-03 2013-05-16 Novartis Ag Device
KR102443606B1 (ko) * 2012-07-03 2022-09-14 노파르티스 아게 시린지
CN110115657A (zh) * 2012-07-03 2019-08-13 诺华股份有限公司 注射器
KR20220062681A (ko) * 2012-07-03 2022-05-17 노파르티스 아게 시린지
AU2018201120B2 (en) * 2012-07-03 2020-03-05 Novartis Ag Syringe
KR20200029611A (ko) * 2012-07-03 2020-03-18 노파르티스 아게 시린지
AU2021203294B2 (en) * 2012-07-03 2023-07-27 Novartis Ag Syringe
KR20220130821A (ko) * 2012-07-03 2022-09-27 노파르티스 아게 시린지
KR102092427B1 (ko) * 2012-07-03 2020-04-17 노파르티스 아게 시린지
TWI632920B (zh) * 2012-07-03 2018-08-21 瑞士商諾華公司 注射器
GB2500092A (en) * 2012-07-03 2013-09-11 Novartis Ag Small volume syringe for ophthalmic solution
EP3656373A1 (fr) * 2012-07-03 2020-05-27 Novartis AG Seringue
CN111249062A (zh) * 2012-07-03 2020-06-09 诺华股份有限公司 注射器
KR102487296B1 (ko) 2012-07-03 2023-01-13 노파르티스 아게 시린지
EP3685826A1 (fr) * 2012-07-03 2020-07-29 Novartis AG Seringue
KR102395557B1 (ko) 2012-07-03 2022-05-09 노파르티스 아게 시린지
WO2014005728A1 (fr) * 2012-07-03 2014-01-09 Novartis Ag Seringue
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
AU2013100071B4 (en) * 2012-07-03 2013-03-28 Novartis Ag Device
GB2500092B (en) * 2012-07-03 2014-02-12 Novartis Ag Syringe
US9220631B2 (en) 2012-07-03 2015-12-29 Novartis Ag Syringe
AU2020201957B2 (en) * 2012-07-03 2021-04-01 Novartis Ag Syringe
CN112972828A (zh) * 2012-07-03 2021-06-18 诺华股份有限公司 注射器
AU2012101677B4 (en) * 2012-07-03 2012-12-20 Novartis Ag Device
EP3470058A1 (fr) * 2012-07-03 2019-04-17 Novartis AG Seringue
KR102341670B1 (ko) 2012-07-03 2021-12-22 노파르티스 아게 시린지
EA031583B1 (ru) * 2012-07-03 2019-01-31 Новартис Аг Шприц
KR20210156865A (ko) * 2012-07-03 2021-12-27 노파르티스 아게 시린지
KR102299177B1 (ko) * 2012-07-03 2021-09-08 노파르티스 아게 시린지
KR20210113413A (ko) * 2012-07-03 2021-09-15 노파르티스 아게 시린지
CN104427972A (zh) * 2012-07-03 2015-03-18 诺华股份有限公司 注射器
EP3685826B1 (fr) 2012-07-03 2021-11-03 Novartis AG Seringue
KR20150030216A (ko) * 2012-07-03 2015-03-19 노파르티스 아게 시린지
EP3381444A1 (fr) * 2012-07-03 2018-10-03 Novartis AG Seringue
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US12115102B2 (en) 2013-03-28 2024-10-15 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11273171B2 (en) 2013-07-12 2022-03-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US12016875B2 (en) 2013-07-12 2024-06-25 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2015061341A1 (fr) * 2013-10-21 2015-04-30 Accuro Technologies Inc. Seringue à double cylindre et son procédé d'utilisation pour la confirmation de placement et injection dans un espace articulaire
US10130777B2 (en) 2014-07-08 2018-11-20 Terumo Kabushiki Kaisha Injection needle
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US12343283B2 (en) 2014-07-15 2025-07-01 Forsight Vision4, Inc. Ocular implant delivery device and method
US11337853B2 (en) 2014-07-15 2022-05-24 Forsight Vision4, Inc. Ocular implant delivery device and method
WO2016018889A1 (fr) * 2014-07-28 2016-02-04 Medical Instrument Development Laboratories, Inc. Glissière de renfort pour outil chirurgical manuel
US10179007B2 (en) 2014-07-28 2019-01-15 Medical Instrument Development Laboratories, Inc. Reinforcing slider for surgical hand tool
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US12251336B2 (en) 2014-11-10 2025-03-18 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11406565B2 (en) 2015-03-10 2022-08-09 Regeneran Pharmaceuticals, Inc. Aseptic piercing system and method
US12201556B2 (en) 2015-11-20 2025-01-21 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11769597B2 (en) 2015-12-03 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US12102560B2 (en) 2016-04-05 2024-10-01 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US10328212B2 (en) 2016-04-22 2019-06-25 Accuro Technologies Inc. Single slider double barrel syringe and method to use same for medical diagnostics, therapeutic use, and placement confirmation and joint space injection
US10905786B2 (en) 2017-03-27 2021-02-02 Regeneron Pharmaceuticals, Inc. Sterilisation method
US10918754B2 (en) 2017-03-27 2021-02-16 Regeneron Pharmaceuticals, Inc. Sterilisation method
US12226613B2 (en) 2017-05-05 2025-02-18 Regeneron Pharmaceuticals, Inc. Auto-injector and related methods of use
US11547801B2 (en) 2017-05-05 2023-01-10 Regeneron Pharmaceuticals, Inc. Auto-injector
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11433186B2 (en) 2017-12-13 2022-09-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US12116622B2 (en) 2018-05-25 2024-10-15 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11439758B2 (en) 2019-06-05 2022-09-13 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US20230080971A1 (en) * 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
KR20230110383A (ko) 2022-01-14 2023-07-24 건양대학교산학협력단 주사기
KR102617251B1 (ko) * 2022-01-14 2023-12-28 건양대학교산학협력단 주사기
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Also Published As

Publication number Publication date
EP1924309A1 (fr) 2008-05-28
CA2622573A1 (fr) 2007-03-29
JP2009508593A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2007035621A1 (fr) Seringue oculaire
CA2498489C (fr) Procede d'administration sub-retinienne d'agents therapeutiques comprenant des steroides, procede servant a concentrer une action pharmacodynamique au niveau de la choroide et de la retine et procedes associes servant a traiter et/ou a prevenir des maladies retiniennes
EP2124857B1 (fr) Appareil pour injection intra-oculaire
KR102511477B1 (ko) 안구 후부 질환을 치료하기 위한 방법 및 디바이스
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
CN104884049A (zh) 用于在人类受试者中治疗眼部疾病的方法和装置
US20060200097A1 (en) Reservoirs with subretinal cannula for subretinal drug delivery
US20140249539A1 (en) Apparatus for Intraocular Injection
JP2003518987A (ja) 眼内注入のためのガイド手段
JP2005516636A (ja) 網膜下への薬剤送達のための方法およびデバイス
JP7489684B2 (ja) 眼感染症を予防するための抗生物質溶液および注射方法
RU2388438C1 (ru) Способ введения лекарственных препаратов в субтеноново пространство у пациентов с оперированной рефрактерной глаукомой
RU2661621C2 (ru) Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
RU2394535C2 (ru) Способ введения лекарственных препаратов в субтеноново пространство у пациентов с оперированной глаукомой
HK1235263A1 (en) Methods and devices for treating posterior ocular disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006803774

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2622573

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008531405

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE